| Thursday 3 April 2003 | ||
| Organizers | W. Kirch (Dresden, Germany) D. Pittrow (Dresden, Germany) |
|
| Sponsors | Sanofi-Synthelabo GmbH (Berlin, Germany) (unrestricted educational grant) | |
Antithrombotic therapy – selective Xa inhibitors |
||
| Session I | ||
| Chairs | W. Kirch (Dresden, Germany) & D. Pittrow (Dresden, Germany) | Abstract No. |
| 09.40 – 10.00 | From heparins to factor Xa inhibitors and beyond S. Alban (Kiel, Germany) |
105 |
| 10.00 – 10.30 | Paradigm shift in antithrombotic therapy (focus on fondaparinux) S.M. Schellong (Dresden, Germany) |
106 |
| 10.30 – 11.00 | Future applications for new factor Xa inhibitors G. Agnelli (Perugia, Italy) |
|
| 11.00 – 11.15 | coffee break | |
| Session II | ||
| Chairs | W. Kirch (Dresden, Germany) & D. Pittrow (Dresden, Germany) | Abstract No. |
| 11.15 – 11.45 | The role of factor Xa in venous and arterial thrombosis L. Drouet (Paris, France) |
107 |
| 11.45 – 12.15 | The ‘principle of caution’ as a guide for future drug development S. Alban (Kiel, Germany) |
107A |
| 12.15 – 13.00 | General discussion | |
| 13.00 | End of workshop | |
